Multiplexing made simple
Cell-based assays
Molecular tests
Spatial biology
OVERVIEW
The ATON System uses optical spectroscopy to quantify molecules
How it Works
Laser light causes the molecules in the sample to vibrate. Sensors collect molecular signatures from scattered light. The software reports the concentrations of each target in the multiplex test panel. Rapid results inform experimental design.
Life Science Strategy
Atonarp will develop and sell less complex, affordable analyzers and reagents for high-multiplex cell-based tests for scientists in pharma/biotech, academia and government. We intend to establish the technology in non-regulated markets first, then continue product development to offer a portfolio of high-value in vitro diagnostic tests.
Cell-based Assays
A comprehensive understanding of fundamental biology, disease pathways, and drug mechanism of action requires the integration of information from a large number of related pathways. Multiplexed measurements are attracting considerable interest in single-cell biology and systems biology. Current methods are expensive and/or difficult to implement.
Atonarp plans to develop optical spectroscopy applications for cell-based assays in basic research and in bioprocessing applications including:
· Immunophenotyping as an alternative to flow cytometry and mass spectrometry
· Cell imaging
· Study cell surface proteins, e.g., multiplex biomarker expression for targeted therapies, immune response.
· Cell count, viability, cytotoxicity assays used to assess effectiveness cell/gene therapies
why?
Count/characterize cell populations and protein expression
What?
Experiments that study cells and target specific components using antibodies
How?
Measure immune response, metabolism, apoptosis, cellular processes, viability
Emergency Department
Atonarp plans to develop tests to assess patients with symptoms of heart attack.
• Over 10 million Americans go to the emergency department with chest pain each year. Although only 13% of them have had a heart attack, but 66% are admitted to the hospital.
• Implementing testing with a high sensitivity troponin test can increase discharge rate from 34% to 75%, which could save $7 billion per year.
Measure cardiac biomarkers
Troponin leaks from dead heart cells. It is used to diagnose heart attack.
Rule-out/Rule-in
Safely discharge low-risk patients or admit patients with heart attack faster.
$
$70 billion cost savings
Discharging patients quickly eases crowding in the ED and allows efficient care of more patients.
ICU/Sepsis
Atonarp plans to develop point-of-care, multiplex tests for inflammatory and sepsis biomarkers in blood.
Inflammatory biomarkers are associated with severe infection and sepsis and can be measured early in acute infection. Research indicates that certain combinations of these biomarkers may be prognostic for “cytokine storm,” which is an out-of-control immune response that is associated with bad outcomes in COVID-19 and sepsis. Our panels will provide rapid results that may give insights about immune response and help inform treatment decisions.
Personalize treatment
Speed matters. Sepsis can progress rapidly and can be fatal. Each hour of delay in giving antibiotics increases risk of death by 7%.
Improve outcomes
Costs $27 billion annually in the U.S.
Measure toxins
Sepsis affects 30 million people worldwide and causes 6 million deaths annually.
Non-invasive testing
Atonarp is developing our multi-laser optical spectroscopy technology for non-invasive, transdermal measurement of glucose to monitor patients with diabetes.
- Globally, 422 million adults are living with diabetes.
- Diabetes caused 1.5 million deaths worldwide. High blood glucose caused an additional 2.2 million deaths by increasing the risks of cardiovascular and kidney diseases.
Measure glucose
Non-invasive testing replaces fingersticks
Adjust Therapy
Modify diet, exercise and medications
Improve management
Better control improves outcomes and reduces costs
Products are under development and not available for sale.